FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3184902103> ?p ?o ?g. }

• W3184902103 endingPage "1170" @default.
• W3184902103 startingPage "1162" @default.
• W3184902103 abstract "Patients with ovarian clear cell carcinoma (OCCC) experience frequent recurrence, which is most likely due to chemoresistance. We used shotgun proteomics analysis and identified upregulation of ezrin-binding phosphoprotein 50 (EBP50) in recurrent OCCC samples. Cytoplasmic and/or nuclear (Cyt/N), but not membranous, EBP50 immunoreactivity was significantly higher in recurrent OCCC as compared with that of primary tumors. OCCC cells expressing cytoplasmic EBP50 were significantly less susceptible to cisplatin (CDDP)-induced apoptosis compared with cells expressing membranous EBP50. Abrogation of resistance following knockdown of cytoplasmic EBP50 was accompanied by decreased XIAP and BCL2, increased BAX and increased caspase-3 cleavage. We found that poly (ADP-ribose) polymerase1 (PARP1), which is involved in DNA damage detection and repair, binds to EBP50 through its PDZ1 domain. CDDP treatment of cells expressing cytoplasmic (but not membranous) EBP50 increased nuclear PARP1 expression, whereas knockdown of EBP50 cells decreased PARP1 expression and activity following CDDP treatment. Finally, OCCC patients with a combination of Cyt/N EBP50 and high PARP1 score had worst the prognosis for overall and progression-free survival. Together, our data suggest that cytoplasmic EBP50 inhibits apoptosis and promotes OCCC survival through stabilization of PARP1 activity and modulation of the XIAP/BCL2/BAX axis. This may increase the likelihood of tumor recurrence, and we therefore suggest a combined analysis for EBP50 and PARP1 may have great utility in OCCC prediction and prognosis." @default.
• W3184902103 created "2021-08-02" @default.
• W3184902103 creator A5009292470 @default.
• W3184902103 creator A5009787677 @default.
• W3184902103 creator A5018146056 @default.
• W3184902103 creator A5022540600 @default.
• W3184902103 creator A5024022304 @default.
• W3184902103 creator A5030946298 @default.
• W3184902103 creator A5045381549 @default.
• W3184902103 creator A5049405145 @default.
• W3184902103 creator A5053022145 @default.
• W3184902103 creator A5058831392 @default.
• W3184902103 creator A5087729609 @default.
• W3184902103 creator A5037194011 @default.
• W3184902103 date "2021-07-29" @default.
• W3184902103 modified "2023-10-18" @default.
• W3184902103 title "Cytoplasmic EBP50 and elevated PARP1 are unfavorable prognostic factors in ovarian clear cell carcinoma" @default.
• W3184902103 cites W1904090062 @default.
• W3184902103 cites W1965734230 @default.
• W3184902103 cites W1976570855 @default.
• W3184902103 cites W1979879868 @default.
• W3184902103 cites W1984515231 @default.
• W3184902103 cites W1990671797 @default.
• W3184902103 cites W2001877789 @default.
• W3184902103 cites W2005959958 @default.
• W3184902103 cites W2033901170 @default.
• W3184902103 cites W2034702779 @default.
• W3184902103 cites W2050979643 @default.
• W3184902103 cites W2058645214 @default.
• W3184902103 cites W2064840876 @default.
• W3184902103 cites W2082547329 @default.
• W3184902103 cites W2086141337 @default.
• W3184902103 cites W2102700781 @default.
• W3184902103 cites W2108830619 @default.
• W3184902103 cites W2108835658 @default.
• W3184902103 cites W2116870857 @default.
• W3184902103 cites W2117897243 @default.
• W3184902103 cites W2136205584 @default.
• W3184902103 cites W2139548721 @default.
• W3184902103 cites W2144144321 @default.
• W3184902103 cites W2282447757 @default.
• W3184902103 cites W2291627101 @default.
• W3184902103 cites W2569161709 @default.
• W3184902103 cites W2621872033 @default.
• W3184902103 cites W2729706724 @default.
• W3184902103 cites W2738919742 @default.
• W3184902103 cites W2755719902 @default.
• W3184902103 cites W2795295129 @default.
• W3184902103 cites W2995820396 @default.
• W3184902103 cites W3039035835 @default.
• W3184902103 cites W3093718293 @default.
• W3184902103 doi "https://doi.org/10.1093/carcin/bgab070" @default.
• W3184902103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34323956" @default.
• W3184902103 hasPublicationYear "2021" @default.
• W3184902103 type Work @default.
• W3184902103 sameAs 3184902103 @default.
• W3184902103 citedByCount "6" @default.
• W3184902103 countsByYear W31849021032022 @default.
• W3184902103 countsByYear W31849021032023 @default.
• W3184902103 crossrefType "journal-article" @default.
• W3184902103 hasAuthorship W3184902103A5009292470 @default.
• W3184902103 hasAuthorship W3184902103A5009787677 @default.
• W3184902103 hasAuthorship W3184902103A5018146056 @default.
• W3184902103 hasAuthorship W3184902103A5022540600 @default.
• W3184902103 hasAuthorship W3184902103A5024022304 @default.
• W3184902103 hasAuthorship W3184902103A5030946298 @default.
• W3184902103 hasAuthorship W3184902103A5037194011 @default.
• W3184902103 hasAuthorship W3184902103A5045381549 @default.
• W3184902103 hasAuthorship W3184902103A5049405145 @default.
• W3184902103 hasAuthorship W3184902103A5053022145 @default.
• W3184902103 hasAuthorship W3184902103A5058831392 @default.
• W3184902103 hasAuthorship W3184902103A5087729609 @default.
• W3184902103 hasConcept C121608353 @default.
• W3184902103 hasConcept C173396325 @default.
• W3184902103 hasConcept C181199279 @default.
• W3184902103 hasConcept C182979987 @default.
• W3184902103 hasConcept C190062978 @default.
• W3184902103 hasConcept C190283241 @default.
• W3184902103 hasConcept C203014093 @default.
• W3184902103 hasConcept C204232928 @default.
• W3184902103 hasConcept C2778293109 @default.
• W3184902103 hasConcept C2778480876 @default.
• W3184902103 hasConcept C2778560582 @default.
• W3184902103 hasConcept C2781199814 @default.
• W3184902103 hasConcept C31573885 @default.
• W3184902103 hasConcept C33195913 @default.
• W3184902103 hasConcept C502942594 @default.
• W3184902103 hasConcept C54355233 @default.
• W3184902103 hasConcept C55493867 @default.
• W3184902103 hasConcept C82381507 @default.
• W3184902103 hasConcept C86803240 @default.
• W3184902103 hasConcept C95444343 @default.
• W3184902103 hasConcept C98424977 @default.
• W3184902103 hasConceptScore W3184902103C121608353 @default.
• W3184902103 hasConceptScore W3184902103C173396325 @default.
• W3184902103 hasConceptScore W3184902103C181199279 @default.
• W3184902103 hasConceptScore W3184902103C182979987 @default.
• W3184902103 hasConceptScore W3184902103C190062978 @default.

• next